L Brands December Comps. Up 1%; Updates Q4 Earnings Outlook - Quick Facts

L Brands, Inc. (LB) reported a 1 percent increase in comparable sales and a 3 percent increase in net sales for the month of December 2017. In addition, the company revised its earnings outlook for the fourth quarter.

The company's net sales for the five weeks ended December 30, 2017 was $2.52 billion, up 3 percent from net sales of $2.44 billion in the year-ago period. Comparable sales increased 1 percent for the latest period.

For the 48 weeks ended December 30, 2017, L Brands reported net sales of $11.59 billion, down from $11.77 billion for year-ago period. Comparable sales decreased 4 percent.

For the 48 week period, the exit of the swim and apparel categories had a negative impact of about 3 percentage points and 5 percentage points to total company and Victoria's Secret comparable sales, respectively.

Looking ahead to the fourth quarter, L Brands said that before the effect of any significant one-time items and including the impact of tax reform legislation, it now expects to report earnings per share of about $2.00, compared to its previous guidance of $1.95 to $2.10 per share.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mallinckrodt plc announced Wednesday that the U.S. Food and Drug Administration or FDA has approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for the treatment of adult patients with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated. Worldwide 5G mobile subscriptions are estimated to exceed 580 million by the end of 2021, according to the Ericsson Mobility Report. With subscriptions increasing at a rate of about a million per day, 5G remains on track to become the fastest adopted mobile generation in history. The growth in subscriptions is being lead by China, North America and the Gulf Cooperation Council markets. Elanco Animal Health Inc. (ELAN) and veterinary biopharmaceutical company Kindred Biosciences, Inc. (KIN) announced Wednesday they have entered into a definitive agreement for Elanco to acquire Kindred for $9.25 per share, or approximately $440 million. The acquisition further accelerates Elanco's...
Follow RTT